Dr. Janaki Sharma's Guide To Radioligand Therapy & Facing Advanced Prostate Cancer
Dr. Janaki Sharma, a medical oncologist at Sylvester Comprehensive Cancer Center-University of Miami Health System, shares guidance on how advanced prostate cancer is treated — and the groundbreaking new treatment options
Facing advanced prostate cancer can be a daunting process that brings out many questions and concerns, especially when it comes to understanding the treatment options, potential side effects, and how your life will be altered.
Here, Dr. Janaki Sharma, a medical oncologist at Sylvester Comprehensive Cancer Center – University of Miami Health System, walks us through the treatment process — from how prostate cancer is monitored to the innovative new options available in the advanced setting.
Your Digital Guide begins below: 3 Chapters / 5 Video Segments
Dr. Janaki Sharma
Sylvester Comprehensive Cancer Center - University of Miami Health System
Hormone therapy, also known as androgen deprivation therapy (ADT), is the foundation of treatment for advanced prostate cancer and works by reducing or blocking testosterone.
Dr. Janaki Sharma
Sylvester Comprehensive Cancer Center - University of Miami Health System
PARP inhibitors can slow disease progression and improve outcomes for eligible patients whose cancer no longer responds to standard hormone treatments.
Dr. Janaki Sharma
Sylvester Comprehensive Cancer Center - University of Miami Health System
Radioligand therapy, such as Pluvicto, delivers targeted radiation to prostate cancer cells by binding to PSMA, a protein commonly found on these cells, while minimizing damage to healthy tissue.
Dr. Janaki Sharma
Sylvester Comprehensive Cancer Center-University of Miami Health System
Prostate cancer that progresses despite hormone therapy can be challenging, but a targeted radiation approach with a therapy called Pluvicto offers a promising new option.
